← Leaderboards
Bingcheng Wang
Case Western Reserve University
$12,028,840
Attributed
$14,999,133
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,999,133 · 11
By mechanism
R01$14,501,220 · 9
P50$391,413 · 1
R21$106,500 · 1
Top collaborators
- Ge Jin5 shared
- Hui Miao5 shared
- Elena B Pasquale1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Hui Miao$790,005
Others in their field
Top investigators on “Cell Motility”
- Kenton M Sanders · University Of Nevada Reno$35,098,811
- Yale E Goldman · University Of Pennsylvania$29,574,325
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$23,000,422
- Peter N Devreotes · Johns Hopkins University$20,714,134
- John Blenis · Harvard University (Medical School)$18,957,548
- Wendell A Lim · University Of California, San Francisco$18,932,063
Research focus
Cell MotilityIn VivoCellsIn VitroSignal TransductionLeadMolecularReportingPhosphorylationBaseAffectLigandsPhosphotransferasesEphrinsTumorGrowthMalignant NeoplasmsNeoplasm MetastasisMemberMigrationResponseSerineMalignant - DescriptorDiagnosis
Grant awards (43)
EphA1 homotypic and EphA1-EphA2 heterotypic interactions in cell regulation$693,134
R01 · FY2025 · CA · contact PI
Role of HIV in KSHV oral transmission$655,512
R01 · FY2025 · CA · contact PI
(PQ1) HIV-infected T-cell exosomes in lung cancer progression$703,784
R01 · FY2024 · CA
(PQ1) HIV-infected T-cell exosomes in lung cancer progression$700,187
R01 · FY2023 · CA
(PQ1) HIV-infected T-cell exosomes in lung cancer progression$774,099
R01 · FY2022 · CA
(PQ1) HIV-infected T-cell exosomes in lung cancer progression$756,944
R01 · FY2021 · CA
Targeting EphA2 in Glioblastoma$508,984
R01 · FY2021 · NS · contact PI
(PQ1) HIV-infected T-cell exosomes in lung cancer progression$732,429
R01 · FY2020 · CA
Targeting EphA2 in Glioblastoma$508,984
R01 · FY2019 · NS · contact PI
Targeting EphA2 in Glioblastoma$508,984
R01 · FY2018 · NS · contact PI
Targeting EphA2 in Glioblastoma$508,984
R01 · FY2017 · NS · contact PI
Targeting EphA2 in Glioblastoma$552,859
R01 · FY2016 · NS · contact PI
EphA2 kinase in prostate cancer$256,089
R01 · FY2016 · CA · contact PI
EphA2 kinase in prostate cancer$69,686
R01 · FY2015 · CA · contact PI
EphA2 kinase in prostate cancer$316,002
R01 · FY2014 · CA · contact PI
Akt-EphA2 Crosstalk in Glioma Invasion$316,002
R01 · FY2014 · CA · contact PI
Akt-EphA2 Crosstalk in Glioma Invasion$306,229
R01 · FY2013 · CA · contact PI
EphA2 kinase in prostate cancer$306,229
R01 · FY2013 · CA · contact PI
EphA2 kinase in prostate cancer$325,775
R01 · FY2012 · CA · contact PI
Akt-EphA2 Crosstalk in Glioma Invasion$316,002
R01 · FY2012 · CA · contact PI
EphA2 kinase in prostate cancer$325,775
R01 · FY2011 · CA · contact PI
Eph Kinase Signaling In Renal Epithelial Cells$321,778
R01 · FY2011 · DK · contact PI
Akt-EphA2 Crosstalk in Glioma Invasion$316,002
R01 · FY2011 · CA · contact PI
Akt-EphA2 Crosstalk in Glioma Invasion$325,775
R01 · FY2010 · CA · contact PI
Eph Kinase Signaling In Renal Epithelial Cells$325,029
R01 · FY2010 · DK · contact PI
Eph Kinase Signaling In Renal Epithelial Cells$328,312
R01 · FY2009 · DK · contact PI
Eph Kinase Signaling In Renal Epithelial Cells$47,100
R01 · FY2009 · DK · contact PI
Eph Kinase Signaling In Renal Epithelial Cells$328,312
R01 · FY2008 · DK · contact PI
EphA2 Agonists as Novel Inhibitors of Tumor Progression$212,231
R01 · FY2007 · CA · contact PI
EphA2 Agonists as Novel Inhibitors of Tumor Progression$265,940
R01 · FY2006 · CA · contact PI
EphA2 Agonists as Novel Inhibitors of Tumor Progression$272,340
R01 · FY2005 · CA
Eph Kinase Signaling in Prostate Cancer$238,613
R01 · FY2004 · CA
EphA2 Agonists as Novel Inhibitors of Tumor Progression$82,553
R01 · FY2004 · CA
EphA2 Agonists as Novel Inhibitors of Tumor Progression$272,340
R01 · FY2003 · CA
Eph Kinase Signaling in Prostate Cancer$238,613
R01 · FY2003 · CA
EphA2 Agonists as Novel Inhibitors of Tumor Progression$306,383
R01 · FY2002 · CA
Eph Kinase Signaling in Prostate Cancer$238,613
R01 · FY2002 · CA
CORE--PEPTIDE BIOCHEMISTRY$135,290
P50 · FY2002 · DK
Eph Kinase Signaling in Prostate Cancer$238,613
R01 · FY2001 · CA
CORE--PEPTIDE BIOCHEMISTRY$135,290
P50 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY$0
P50 · FY2001 · DK
CORE--PEPTIDE BIOCHEMISTRY$120,833
P50 · FY2000 · DK
NOVEL THERAPY FOR IMMUNE COMPLEX-INDUCED KIDNEY DISEASE$106,500
R21 · FY2000 · DK